Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 76

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 76
---
 the clinical study will expand from the nine clinical sites in the United States to include an additional site in the United States and two clinical trial sites in Europe and that the Company has randomized more than 45 participants in the study.

We expect our R&D expenses to increase substantially for the foreseeable future as we continue with the SKNJCT-003 study and trials.

The principal risks related to the Company's future performance are that the trials are unsuccessful, the Company does not receive FDA approval to proceed with the next stage of its research and development, or the Company is unsuccessful in obtaining future funding needed to continue its research and development. These are customary risks for a development stage pharmaceutical Company and are less acute than for a Company with a less advanced product. Nevertheless, there can be no assurance that the Company will be able to complete its trials of the MNA, that the trials will be successful, or that the product will ultimately reach commercialization.

Other income:

Finance income was $23,866 and $0 for the three months ending March 31, 2025 and 2024, respectively. Finance income for the three months ended March 31, 2025 relates to interest income earned on short-term money market investments.

The following table outlines our statements of loss and comprehensive loss for the years ended December 31, 2024 and 2023:

|                                               |     | Years ended December 31, |   |     |            |   |     |            |   |
|                                               |     |                     2024 
                        $ |   |     |       2023 
          $ |   |     |     Change |   |
| General and administrative                    |     |                7,653,116 |   |     |  4,536,367 |   |     |  3,116,749 |   |
| Research and development                      |     |                3,527,786 |   |     |    193,578 |   |     |  3,334,208 |   |
| Total operating expenses                      |     |               11,180,902 |   |     |  4,729,945 |   |     |  6,450,957 |   |
| Loss from operations                          |     |              (11,180,902 | ) |     | (4,729,945 | ) |     | (6,450,957 | ) |
| Finance (income) expense, net                 |     |                  (25